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Introduction: Mesenchymal stem cells (MSCs) are widely investigated in clinical researches to treat various diseases.
Classic culture medium for MSCs, even for clinical use, contains fetal bovine serum. The serum-containing medium
(SCM) seems a major obstacle for MSCs-related therapies due to the risk of contamination of infectious pathogens.
Some studies showed that MSCs could be expanded in serum free medium (SFM); however, whether SFM would
change the biological characteristics and safety issues of MSCs has not been well answered.
Methods: Human umbilical cord mesenchymal stem cells (hUC-MSCs) were cultured in a chemical defined serum
free medium. Growth, multipotency, surface antigen expression, telomerase, immunosuppressive ability, gene
expression profile and genomic stability of hUC-MSCs cultured in SFM and SCM were analyzed and compared side
by side.
Results: hUC-MSCs propagated more slowly and senesce ultimately in SFM. SFM-expanded hUC-MSCs were different
from SCM-expanded hUC-MSCs in growth rate, telomerase, gene expression profile. However, SFM-expanded
hUC-MSCs maintained multipotency and the profile of surface antigen which were used to define human MSCs.
Both SFM- and SCM-expanded hUC-MSCs gained copy number variation (CNV) in long-term in vitro culture.
Conclusion: hUC-MCSs could be expanded in SFM safely to obtain enough cells for clinical application, meeting
the basic criteria for human mesenchymal stem cells. hUC-MSCs cultured in SFM were distinct from hUC-MSCs
cultured in SCM, yet they remained therapeutic potentials for future regenerative medicine.Introduction
Mesenchymal stem cells (MSCs) possess the ability of
self-renew and multipotency. These cells can replicate
in vitro and have the potential to differentiate to bone,
fat and cartilage tissues [1]. Numerous preclinical and
clinical studies have demonstrated that MSCs hold an
alluring prospect as cellular therapies, based on their* Correspondence: zhibohan@163.com; hanzhongchao@hotmail.com
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suppressive abilities. MSC-based tissue-engineering ap-
proaches could treat patients with long bone defects
[2,3]. Co-transplantation of MSCs with HLA-disparate
hematopoietic stem cells could accelerate lymphocyte re-
covery and reduce the risk of graft failure [4]. For the
small effect on T-cell responses to pathogens, infusion
of MSCs suppressed alloantigen-induced T-cell function
and might be a promising therapy for graft-versus-host
disease [5,6]. MSCs, described as a very rare population
in bone marrow by Friedenstein and colleagues [7], need
to be expanded in vitro to achieve the amount required
for administration. Several safety-related issues haveThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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expanded MSCs. It is not clear whether MSCs could
maintain genomic stability during expansion in vitro and
whether injection of MSCs could lead to cancer in vivo.
Many studies have demonstrated that MSCs will not
undergo malignant transformation after long-term in vitro
culture in serum-containing culture [8]. Other studies on
pluripotent stem cells have revealed that the number of
chromosomes and the copy number of specific regions in
the genome of embryonic stem cells or induced pluripo-
tent stem cells could mutate in the process of in vitro
expansion [9-14]. Similarly, copy number variation (CNV)
was found in adipose tissue-derived MSCs [15] after long-
term culture, even though they did not undergo malignant
transformation. Previous studies paid much attention to
the safety issues of MSCs cultured in serum-containing
medium (SCM) [16]. However, it is not desirable to pre-
pare MSCs for clinical application in SCM. The utmost
problem associated with bovine and human serum is the
safety issue. Bovine serum might contain zoonotic viruses
(including prion), which cannot be cleaned up during the
process of preparing MSCs for clinical use. Human serum
might contain undetectable pathogen, which could easily
spread between human beings during stem cell transplant-
ation. From this perspective, human serum is more dan-
gerous than serum of animals. In recent years, some
human serum or human platelet lysate products are solv-
ent/detergent treated, which makes them much less likely
to transmit an infectious disease, without deleting the risk
completely [17].
In addition, serum is ill-defined, has a high degree of
batch-to-batch variation, is hard to standardize and can
harm the process control and stability of quality and
production. Serum-free medium (SFM) is an ideal sys-
tem for cellular therapy. MSCs expanded in SFM per-
form much better in quality control and stability. Many
previous studies focused on increasing attachment and
growth of MSCs in SFM [18]. Other studies evaluated
the clinical application related biological characteristics
of SFM-expanded MSCs [19,20]. However, the safety and
efficacy of MSCs cultured in SFM have not been well eval-
uated [21]. In this study we investigated whether human
umbilical cord mesenchymal stem cells (hUC-MSCs) ex-
panded in SFM change their biological characteristics and
clinical safety-related issues, which included genome and
transcriptome stability.
Methods
Growth characteristics of MSCs in serum-free medium
hUC-MSCs derived from five different donors were iso-
lated from Wharton’s jelly by enzymatic digestion [22] and
frozen in a master cell bank after short-term expansion in
SCM. This study is approved by the Institutional Review
Board of the Chinese Academy of Medical Science andPeking Union Medical College. Umbilical cords were ob-
tained following the ethical guidelines with written in-
formed consent from donors. All experimental research of
this study was in compliance with the Helsinki Declar-
ation. After recovery from the master cell bank, hUC-
MSCs were cultured on a tissue culture surface with SCM
that contained 10% fetal bovine serum (ExCell Bio, Shanghai,
China) or on a chemically treated cell culture surface
(CellBIND; Corning Incorporated, Corning, NY, USA)
with a chemically defined SFM (MSCGM-CD; Lonza,
Walkersville, MD, USA), at 37°C and 5% carbon dioxide.
After reaching 90% confluence, hUC-MSCs were detached
and subcultured at a ratio of 1:3 until reaching senescence.
The time needed to obtain confluence for every passage
was recorded to calculate the population-doubling time.
β-galactosidase were analyzed at late passage by a cellular
senescence assay kit (Millipore, Billerica, MA, USA) follow-
ing the manufacturer’s protocol. In this assay, senescent
cells were stained as a distinctive blue color.
Differentiation of MSCs cultured in serum-free medium
For osteogenic and adipogenic differentiation, SFM-
expanded hUC-MSCs at the 10th passage were seeded in
24-well plates at a concentration of 5 × 104 cells per well.
The StemPro Adipogenesis Differentiation Kit (A10070-
01; GIBCO, Grand Island, NY, USA) and the Osteogenesis
Differentiation Kit (A10072-01; GIBCO) were used as
the differentiation-inducing medium. The medium was
refreshed twice every week. After 21 days of differenti-
ation, cells were fixed in 70% ethanol and stained with Ali-
zarin Red S (for osteogenic differentiation) or Oil Red O
(for adipogenic differentiation). For chondrogenic differen-
tiation, 4 × 105 SFM-expanded hUC-MSCs at the 10th
passage were suspended in 1 ml StemPro Chondrogenesis
Differentiation Kit (A10071-01; GIBCO) and distributed
to 15 ml centrifuge tubes. Cells were centrifuged at 500 ×
g for 5 minutes and then placed in an incubator with the
caps loosened. The chondrogenic culture was refreshed
twice every week. After 21 days of chondrogenesis, the
pellets were fixed in 4% formaldehyde, cut to 5 μm and
stained by Toluidine blue.
Flow cytometric analysis
hUC-MSCs expanded in SFM at the 10th passage were
characterized by flow cytometric analysis for specific anti-
gens. For the analysis of cell surface markers, hUC-MSCs
expanded in SFM were harvested after detachment,
washed in phosphate-buffered saline and then incubated
with phcoerythrin-labeled or fluorescein isothiocyanate-
labeled monoclonal antibodies against CD14 (12-0149-42;
eBioscience, San Diego, CA, USA), CD19 (555413; BD
Biosciences, Franklin Lakes, NJ, USA), CD34 (555821; BD
Biosciences), CD45 (103105; BioLegend, San Diego, CA,
USA), CD73 (550257; BD Biosciences), CD90 (555596; BD
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(555552; BD Biosciences) and HLA-DR (555812; BD Bio-
sciences). For analyzing the expression of Nestin, which is
an intracellular marker, SFM-expanded hUC-MSCs were
fixed and permeabilized by the Cytofix/Cytoperm™ Fixation/
Permeabilization Kit (554714; BD Biosciences). The cells
were then stained by phcoerythrin-conjugated antibodies
against Nestin. CellQuest was used to perform the analysis
on FACS Calibur’ (BD Biosciences, San Jose, CA, USA).
Telomerase reverse transcriptase analysis
RNA was extracted from SCM-expanded and SFM-
expanded hUC-MSCs in SFM using the E.Z.N.A Total
RNA Kit (Omega Bio-Tek, Norcross, GA, USA). cDNA was
synthesized by M-MLV Reverse Transcriptase (Invitrogen,
Carlsbad, CA, USA). TaqMan-based real-time quantitative
PCR assay was used to analyze the expression of hTERT
(the human telomerase catalytic subunit gene) [23]. For
each PCR run, a 20 μl reaction mix was prepared with
10 μl TaqMan Gene Expression Master Mix (2×; Applied
Biosystems, Warrington, UK), 1 μl of 10 μM upper primer,
1 μl of 10 μM lower primer, 1 μl of 10 μM probe, 1 μl of
cDNA and 6 μl ddH20. The reaction mixes were then
placed in Applied Biosystems real-time PCR System 7300
with the following thermal cycling conditions: 50°C for
2 minutes, 95°C for 10 minutes, 55 cycles including 95°C
for 15 seconds and 60°C for 1 minute. RPLP0 was used as
a reference gene. cDNA prepared from HeLa cells was
used as a positive control.
Immunoregulation analysis
We used lymphocyte proliferation and interferon gamma
(IFNγ) analysis, which was described by previous studies
[24,25], to evaluate the immunosuppressive ability of
hUC-MSCs after culture in SFM. In brief, SCM-derived
and SFM-derived hUC-MSCs were irradiated (60 Gy)
and then cultured in 96-well cell culture plates. Two
hours later, human peripheral blood mononuclear cells
(hPBMCs) were added to hUC-MSCs and cultured with
PHA (Sigma, St. Louis, MO, USA) and interleukin-2
(Peprotech, Rocky Hill, NJ, USA). hPBMCs were co-
cultured with hUC-MSCs for 3 days. BrdU was added
18 hours before detection. Cell proliferation was mea-
sured by BrdU incorporation assay (Roche, Mannheim,
Germany). Supernatant were harvested for IFNγ analysis
(eBioscience).
Genetic stability of MSCs cultured in SFM and in SCM
Two pairs of samples that expanded in SFM and SCM
were sent to CapitalBio Co. (Beijing, China) for array-
based comparative genomic hybridization (aCGH) ana-
lysis following the protocol described on the website
of CapitalBio Co. [26]. Briefly, the genomic DNA was
extracted and purified from hUC-MSCs by phenol–chloroform. According to the quality control require-
ments of NimbleGen (Madison, WI, USA), the genomic
DNA was undegraded and has A260/A280 ≥ 1.8 and
A260/A230 ≥ 1.9. NimbleGen human whole-genome til-
ing arrays containing up to 4.2 million probes, spanning
the human genome with a median probe spacing of
2,509 base pairs (Human CGH 3x720K Whole-Genome
Tiling v3.0 Array, 05547717001; NimbleGen), were uti-
lized for aCGH analysis. Genomic DNA extracted from
SCM-expanded or SFM-expanded hUC-MSCs at the
10th passage was labeled with Cy3. DNA isolated from
hUC-MSCs at the third passage, derived from the same
donors as those from whom serum-free culture or
serum-containing culture were established, were labeled
with Cy5 and used as reference samples.
Test (10th passage) and reference (3rd passage) samples
were co-hybridized onto arrays and scanned using a
MS200 scanner (NimbleGen) with 2 μm resolution. Cy3
and Cy5 signal intensities were computed and normalized
using the q-spline method [27]. Segments with |mean log2
ratio| ≥ 0.25 and at least five consecutive probes were
scored as aberrant DNA copy number changes.
Transcriptome analysis
Three pairs of hUC-MSC samples, before and after ex-
pansion in SFM, were sent to CapitalBio Co. for mRNA
microarray analysis. Total RNA was extracted and then
qualified by formaldehyde agarose gel electrophoresis.
After being quantitated spectrophotometrically, 1 μg total
RNA was used to synthesize double-stranded cDNA and
then produced biotin-tagged cRNA using the Messa-
geAmp™ II aRNA Amplification Kit (Invitrogen). Accord-
ing to the protocol from Affymetrix (Santa Clara, CA,
USA), bio-tagged cRNA was fragmented and hybridized to
Human Genome U133 Plus 2.0 containing over 47,000
transcripts. After hybridizing, the arrays were washed,
stained by Affymetrix Fluidics Station 450 and scanned
by GeneChip Scanner 3000. The intensity values of dif-
ferent microarray were normalized and log2 trans-
formed using the RMA gene core algorithm provided
by the Expression Console (Affymetrix). Genes with at
least twofold changes were selected for further analysis.
The Molecule Annotation System (online analysis sys-
tem provided by CapitalBio Co.) was used to perform
Gene Ontology and pathway analysis. Microarray data
were deposited into a public database [Gene Expression
Omnibus:GSE62665].
Real-time PCR analysis
Real-time PCR was used to validate the data obtained from
the mRNA microarray. Twelve differentially expressed genes
including six upregulated genes and six downregulated
genes were selected for validation by real-time PCR. These
12 genes included genes related to the cell cycle pathway,
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PIK3R1 were selected because they implicated in a large
number of pathways. GoTaq Green Master Mix (Promega,
Madison, WI, USA) was used for real-time PCR in the
7300 real-time PCR System (Applied Biosystems). Relative
expression levels were calculated using ΔΔCT method.
Seven housekeeping genes were selected as the candidates
of reference genes, and we used geNorm [28] for choosing
the most stably expressed housekeeping genes as reference
genes for data analysis.
Results
Growth characteristics of MSCs in serum-free medium
As shown in Figure 1a,b, hUC-MSCs maintained a fibro-
blastoid appearance in SFM, without noticeable morpho-
logical difference to cells expanded in SCM. The major
difference between SFM-cultured and SCM-cultured
hUC-MSCs was the growth rate and proliferating lifespan
in vitro. Compared with hUC-MSCs expanded in SCM, the
population-doubling time of hUC-MSCs cultured in SFM
was prolonged significantly, which meant hUC-MSCs pro-
liferated more slowly in SFM. The population-doubling
time of SCM-cultured hUC-MSCs was maintained rela-
tively constant, which was shorter than 2 days before the
20th passage (Figure 1c). The population-doubling time of
SFM-cultured hUC-MSCs was very unsteady, which
increased with passaging until the senescent stage.
Four out of five hUC-MSCs in this study showed a
much shorter lifespan in SFM compared with that in
SCM (Figure 1d). They entered the senescence phase be-
tween the 10th and 16th passages, which was equivalent
to approximately 15 to 20 population doublings. Only
one sample displayed a better proliferating capacity in
SFM, which reached the senescence phase at the 26th
passage. In SCM, all hUC-MSCs in this study did not
show any senescent sign before the 30th passage (ap-
proximately 47 population doublings).
Actually, we tested at least three different commercial
SFMs. In all of them, hUC-MSCs showed much slower
growth rate and shorter in vitro lifespan compared with
that in SCM (Figure 1e). This implied that SFM for MSCs
still needs further modification to meet the requirements
of growth support. hUC-MSCs cultured in SFM showed a
progressive decrease in growth rate and ultimately
achieved senescence (Figure 1f). No immortalization or
malignant transformation was observed in the culture of
hUC-MSCs in SFM.
Multipotency of serum-free medium-expanded hUC-MSCs
Multipotency of SFM-expanded hUC-MSCs at the 10th
passage was evaluated by osteogenic, adipogenic and
chondrogenic differentiation. After 21 days of inducing
culture, osteogenesis, adipogenesis and chondrogenesis
were analyzed by Alizarin Red, Oil Red O and ToluidineBlue separately. As showed in Figure 2a,b,c, SFM-expanded
hUC-MSCs differentiate to osteocytes, adipocytes and
chondrocytes, which indicates that hUC-MSCs maintained
multipotency after in vitro expansion in SFM.
Specific surface antigen expression
Flow cytometric analysis of SFM-expanded hUC-MSCs at
the 10th passage is presented in Figure 2d. hUC-MSCs cul-
tured in SFM expressed CD105, CD73, CD90 and HLA-
ABC and lacked expression of CD34, CD45, CD14, CD19
and HLA-DR, which met the minimal criteria for identify-
ing human MSCs [29]. In this study, all surface marker ex-
pression patterns of SFM-expanded hUC-MSCs were
similar to those of SCM-expanded hUC-MSCs. Both SFM-
expanded and SCM-expanded hUC-MSCs were positive
for Nestin, which were considered to encompass features
attributed to hematopoietic niche [30].
Expression of hTERT
Activation or upregulation of hTERT is very important for
malignant transformation and immortalization of normal
human cells [31,32]. It is therefore necessary to analyze the
expression of hTERT in MSCs that were cultured in SFM
before clinical application. There is controversy about the
expression of hTERT in MSCs. Based on the analysis of the
telomeric-repeat amplification protocol and PCR, Bernardo
and colleagues did not find any detectable telomerase in
human bone marrow-derived MSCs [33]. However, in
Parsch and colleagues’ study, telomerase could be detected
in bone marrow MSCs by the telomeric-repeat amplifica-
tion protocol [34]. Using a TaqMan-based real-time PCR
assay, we found that hTERT was expressed in hUC-MSCs
cultured in SCM at a very low level (Figure 2e). Neverthe-
less, after culture in SFM, no signal about hTERT could be
detected even after 55 PCR cycles (Additional file 1). Thus,
we claimed that hUC-MSCs possessed expression of
hTERT, but lost it in SFM.
Immunosuppressive ability of serum-free medium-
expanded hUC-MSCs
To study whether SFM-expanded hUC-MSCs maintained
their immunosuppressive ability, we performed an in vitro
co-culture experiment. First, we analyzed the effect of
SFM-expanded hUC-MSCs on inhibiting proliferation of
activated hPBMCs by BrdU incorporation assay. Our data
showed that SFM-expanded hUC-MSCs could inhibit
proliferation of activated hPBMCs (Figure 2f). We then
measured the IFNγ concentration in supernatant of
the co-culture system by enzyme-linked immunosorbent
assay. We found that IFNγ amounts in supernatant were
significantly reduced when MSCs were added (Figure 2g).
Besides, there was no significant difference between SCM-
expanded and SFM-expanded hUC-MSCs on inhibiting
proliferation or IFNγ secretion of activated hPBMCs.
Figure 1 In vitro growth characteristics of human umbilical cord mesenchymal stem cells cultured in serum-free medium. Both in SCM
(a) and in SFM (b), human umbilical cord mesenchymal stem cells (hUC-MSCs) maintained fibroblast-like morphology (40×). (c) Calculated
population-doubling time. Open boxes, hUC-MSCs expanded in SFM; filled boxes, hUC-MSCs expanded in serum-containing medium (SCM).
SFM-expanded hUC-MSCs possessed a much longer calculated population-doubling time. (d) In vitro lifespan of hUC-MSCs derived from five different
donors. (e) Paired t test was used to compare the lifespan of hUC-MSCs cultured in SFM and SCM. A significant different lifespan between SFM-derived
and SCM-derived hUC-MSCs was observed. (f) Senescence-associated β-galactosidase activity analysis of SFM-expanded hUC-MSCs at late passage.
Blue stain shows senescent cells (×200).
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Figure 2 Induced differentiation, flow cytometric and immunosuppressive ability analysis of human umbilical cord mesenchymal stem
cells expanded in serum-free medium. After differentiation induction, (a) osteogenesis was confirmed by Alizarin Red (×40), (b) adipogenesis
was stained by Oil Red O (×200) and (c) chondrogenesis was analyzed by Toluidine Blue (×100). (d) Serum-free medium (SFM)-expanded human
umbilical cord mesenchymal stem cells (hUC-MSCs) at the 10th passage were labeled with antibodies against human antigens CD14-PE, CD19-PE,
CD34-FITC, CD45-PE, CD73-PE, CD90-PE, CD105-PE, HLA-ABC-FITC, HLA-DR-PE and Nestin-PE. (e) Expression of hTERT in hUC-MSCs. Graph shows
the level of hTERT transcripts of hUC-MSCs cultured in serum-containing medium (SCM) and SFM (n = 5). Values presented as ratio of positive
control (HeLa cells). Immunosuppressive ability of hUC-MSCs was evaluated by co-culturing with human peripheral blood mononuclear cells
(hPBMCs). (f) Proliferation of hPBMCs was quantified based the measurement of BrdU incorporation during DNA synthesis. (g) Level of interferon
gamma (IFN-γ) in the supernatant was determined by ELISA.
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of MSCs cultured in SFM and in SCM
Two pairs of hUC-MSCs (sample 2 and sample 4) at the
10th passage, propagated in SFM and SCM, were assessed
by aCGH. Both of the samples showed CNV during
in vitro culture, no matter whether in SFM or SCM. There
was no huge unbalanced genome alteration in SFM-
expanded or SCM-expanded hUC-MSCs (Figure 3a,b,c,d).
As shown in Table 1 and marked in Figure 3f, a total of
238 CNV segments were observed in this study: 107 seg-
ments were gained and the other 131 segments were lost.
The length of affected regions varies from 4 kb to 25 Mb,
with an average of 154 kb. For sample 2, more CNV was
found in SFM than in SCM. However, sample 4 cultured
in SCM gained much more CNV than that cultured in
SFM. There is therefore no significant difference between
SCM-cultured and SFM-cultured MSCs on genomic sta-
bility in this study.
The loss in chr3:181315609 to 181344028, which was
found in both of the SFM-derived hUC-MSCs, didFigure 3 Array-based comparative genomic hybridization analysis of
serum-free medium and serum-containing medium. Huge unbalanced
in which each chromosome was differentiated by color. (a) Sample 2 in se
(SCM). (c) Sample 4 in SFM. (d) Sample 4 in SCM. (e) A copy number variat
observed in both of the SFM-expanded human umbilical cord mesenchym
SCM-expanded samples (blue arrow). (f) CNV identified by array-based com
were mapped onto the human genome for four hUC-MSC clones. Each indnot appear in either of the SCM-expanded hUC-MSCs
(Figure 3e). No annotated genes were located in this region,
thus the CNV observed only in SFM-expanded hUC-MSCs
might have little or no role in altering biological character-
istics. Further investigation is needed to study whether the
CNV observed only in SFM-expanded hUC-MSCs was im-
plicated, directly or indirectly, in a gene expression regula-
tory role. Further research was also needed to identify
whether the genetic mutation was a consequence of cul-
turing in SFM. In addition, absolute values of the log2
ratio of CNV segments observed in this study averaged
0.31, indicating that only a small subpopulation of
hUC-MSCs contained these alterations. In other words,
hUC-MSCs, at least cultured hUC-MSCs, were a hetero-
geneous population in the genome.
Microarray analysis of mRNA in hUC-MSCs expanded in
serum-free medium
hUC-MSCs from three different donors were analyzed by
mRNA chip before and after expansion in SFM. Figure 4human umbilical cord mesenchymal stem cells expanded in
genome alteration was not obvious in the single-panel rainbow plot,
rum-free medium (SFM). (b) Sample 2 in serum-containing medium
ion (CNV) segment (chr3:181315609 to 181344028), which was
al stem cells (hUC-MSCs; red arrow), was not observed in either of the
parative genomic hybridization in culture. Amplifications and deletions
ividual CNV is marked: red circle, amplification; green circle, deletion.
Table 1 Summary of CNV observed in SFM-expanded and SCM-expanded hUC-MSCs
Sample Deletion Amplification
Number of CNV segments Sum of CNV length (base pairs) Number of CNV segments Sum of CNV length (base pairs)
Sample 4 in SFM 10 319568 11 241958
Sample 4 in SCM 50 27084926 92 7188316
Sample 2 in SFM 31 937255 19 444733
Sample 2 in SCM 16 342620 9 200333
CNV, copy number variation; hUC-MSCs, human umbilical cord mesenchymal stem cells; SCM, serum-containing medium; SFM, serum-free medium.
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tions between hUC-MSC samples. Six samples were di-
vided into two groups. In the first group, we found all
hUC-MSCs cultured in SFM. All hUC-MSCs expanded in
SCM fell into the second group. The separation of SFM-Figure 4 Clustering of gene expression for serum-free
medium-cultured and serum-containing medium-cultured
human umbilical cord mesenchymal stem cells. Two different
clusters (expanded in serum-free medium and in serum-containing
medium) were quite obvious. Green, downregulation; red, upregulation.expanded hUC-MSCs from SCM-expanded hUC-MSCs
was very distinctive.
Gene Ontology analysis of genes with differential expres-
sion revealed that cell cycle, mitosis and cell proliferation
were changed significantly in SFM-expanded hUC-MSCs
(Tables 2 and 3). Similarly, pathway enrichment indi-
cated that many differentially expressed genes in SFM-
expanded hUC-MSCs were involved in the cell cycle
pathway (Tables 4 and 5). This is consistent with what
we observed in in vitro culture: hUC-MSCs grow more
slowly in SFM compared with growth in SCM.
We found that 34 genes in the cell cycle pathway were
downregulated (Figure 5) in SFM culture. Many cyclin
and cyclin-dependent kinase (CDK) genes were in the list
of downregulated genes. Considering that cyclin and
CDK play the role of key regulator in the cell cycle [35],
the downregulation of cyclin and CDK might explain
why hUC-MSCs proliferated more slowly in SFM. Besides,
we also found that almost all genes in Mini-Chromosome
Maintenance (MCM) complex were downregulated in
SFM. MCM, as a key component of the prereplication
complex, is very important for the initiation and elong-
ation of DNA replication [36,37]. Downregulation of
MCM might suppress the synthesis of DNA and then slow
the proliferation of hUC-MSCs in SFM. Furthermore,
genes encoding growth factor and their receptor, such asTable 2 Gene Ontology (GO) term enriched by
upregulated genes after expansion in serum-free medium
(top 10)
GO term Count
GO:0006355 regulation of transcription, DNA dependent 57
GO:0006350 transcription 45
GO:0007165 signal transduction 43
GO:0006955 immune response 42
GO:0044419 interspecies interaction between organisms 36
GO:0019882 antigen processing and presentation 30
GO:0002474 antigen processing and presentation of
peptide antigen via MHC class I
30
GO:0007275 development 23
GO:0007155 cell adhesion 22
GO:0006468 protein amino acid phosphorylation 21
Table 3 Gene Ontology (GO) term enriched by
downregulated genes after expansion in serum-free
medium (top 10)
GO term Count
GO:0007049 cell cycle 92
GO:0006355 regulation of transcription, DNA dependent 87
GO:0006350 transcription 86
GO:0007165 signal transduction 77
GO:0051301 cell division 61
GO:0007067 mitosis 55
GO:0007275 development 52
GO:0006468 protein amino acid phosphorylation 43
GO:0007155 cell adhesion 41
GO:0006260 DNA replication 38
Table 5 Pathways for downregulated genes after
expansion in serum-free medium (top 10)
Pathway Gene symbol Count
Cell cycle BUB1; BUB1B; CCNA2; CCNB1;
CCNB2; CCNE2; CDC20; CDC23;
CDC25A; CDC25C; CDC45L; CDC6;
CDC2; CDK2; CDKN2C; CHEK1;
ESPL1; MAD2L1; MCM2; MCM7;
MCM3; MCM4; MCM5; MCM7;
ORC1L; PLK1; PTTG1; SKP2;





CCL2; CCL26; CXCL1; CXCL3;
CXCL5; CXCL6; TNFSF13B; EGF;
EGFR; FLT1; IL11; IL1A; IL1B; IL6;
IL7R; IL8; INHBA; LIF; PDGFC;
PF4V1; CCL14; TGFB1; TGFB2;
TNFRSF11B; VEGFA
25
Focal adhesion ACTB; COL4A6; COL6A1; EGF;
EGFR; FLNB; FLT1; GRLF1; ITGA4;
ITGA5; ITGA6; ITGB3; MAPK8;
MYLK; PAK2; PDGFC; PDPK1;





ACTB; BDKRB1; DIAPH3; EGF;
EGFR; FGF1; FGF2; FGF13; GRLF1;
IQGAP3; ITGA4; ITGA5; ITGA6;
ITGB3; MYH9; MYLK; NRAS;




DUSP4; EGF; EGFR; FGF1; FGF2;
FGF13; FLNB; IL1A; IL1B; MAPK8;
MAPKAPK2; NRAS; PAK2; PRKACB;
19
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lated in hUC-MSCs cultured in SFM. Accordingly, a de-
crease in growth factor and growth factor response might
also suppress the growth rate of hUC-MSCs in SFM [38].
Our data also revealed that some genes (RFC3, RFC4,
RFC5, EXO1, POLE2) involved in the mismatch repair and
nucleotide excision repair pathway were downregulated in
SFM-expanded hUC-MSCs. There are two possible rea-
sons that could explain this phenomenon: instability ofTable 4 Pathways for upregulated genes after expansion
in serum-free medium (top 10)
Pathway Gene symbol Count















Jak-STAT signaling pathway IL20RB; JAK3; LIFR; PIK3R1;
PIK3R3; SPRY1; STAT2
7
Axon guidance CXCL12; EPHA4; EPHB6;
SRGAP1; SRGAP3; SRGAP2
6
Focal adhesion FN1; ITGA10; ITGB8; PDGFD;
PIK3R1; PIK3R3
6
Acute myeloid leukemia PIK3R1; PIK3R3; PML;
RUNX1T1; ZBTB16
5
Phosphatidylinositol signaling system IMPA2; PIK3C2A; PIK3C3;
PIK3R1; PIK3R3
5
Apoptosis CFLAR; IL1R1; IRAK4;
PIK3R1; PIK3R3
5





DNA polymerase FEN1; MCM2; MCM7; MCM3;
MCM4; MCM5; MCM7; POLA1;
POLA2; POLE2; PRIM1; PRIM2;
RFC2; RFC3; RFC4; RFC5;
RNASEH2A
16
Cell adhesion molecules CD276; CDH2; CLDN1; ITGA4;
ITGA6; JAM3; NEGR1; NEO1;
NRXN3; PDCD1LG2; PTPRF;
PVR; PVRL2; SDC1; VCAN
15
Gap junction CDC2; EGF; EGFR; GNAS; NRAS;
PDGFC; PLCB1; PRKACB; PRKCA;
TUBA4A; TUBB2A; TUBB; TUBB2C;
TUBB6
14
Pyrimidine metabolism CTPS; POLA1; POLA2; POLE2;
POLR2D; POLR3G; PRIM1; PRIM2;
RRM1; RRM2; TK1; TYMS; UCK2
13
Purine metabolism GART; PDE7B; PDE8A; PFAS; POLA1;
POLA2; POLE2; POLR2D; POLR3G;
PRIM1; PRIM2; RRM1; RRM2
13genome and reduced growth rate. The aCGH data did
not support a striking increase of CNV in SFM-expanded
hUC-MSCs, so we cannot blame genome instability for
the downregulation of DNA repair-related genes. Reduced
growth might thus be a more reasonable explanation. A
reduced growth rate led to fewer DNA replications and
less DNA errors. So the requirements for mismatch repair
Figure 5 Upregulated and downregulated genes in the cell cycle pathway after expansion in serum-free medium. BUB1, BUB1B, CCNA2,
CCNB1, CCNB2, CCNE2, Cdc20, Cdc23, Cdc25A, Cdc25C, Cdc45L, Cdc6, Cdc2, CDK2, CDKN2C, CHEK1, ESPL1, MAD2L1, MCM2, MCM7, MCM3, MCM4,
MCM5, MCM7, ORC1L, PLK1, PTTG1, SKP2, SMAD3, TFDP1, TGFB1, TGFB2, WEE1, YWHAH and YWHAZ were downregulated after culture in serum-free
medium (SFM). Only Cdc14 was upregulated during expansion in SFM. Red, genes that were upregulated; green, genes that were downregulated.
MAPK, mitogen-activated protein kinase; MCM, Mini-Chromosome Maintenance.
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http://stemcellres.com/content/5/6/132and nucleotide excision repair were reduced in SFM-
expanded hUC-MSCs. Interestingly, we observed at least
five histone-related genes upregulated in SFM-expanded
hUC-MSCs: HIST1H2AC, HIST1H2BC, HIST1H2BD,
HIST1H2BK, HIST1H4H. However, we have no idea why
histone increased their expression level in SFM-expanded
hUC-MSCs, and thus this needs to be further studied.
Real-time PCR validation
To confirm and strengthen the findings derived from
the mRNA chip, we selected 12 genes and measured
their expression level by real-time PCR. As shown in
Figure 6, almost all genes analyzed by real-time PCR
showed a similar expression profile in the mRNA chip.
Real-time PCR data also indicated that genes involved in
the cell cycle pathway (CCNA2, CDC20, CDK1) were
downregulated, while HIST1H2AC and HIST1H2BC were
upregulated in SFM-expanded hUC-MSCs.Discussion
Attaching and proliferating on plastic is a well-described
property of MSCs. Fetal bovine serum provides abun-
dant attachment and growth factors that are essential for
MSC maintenance and growth. Some SFMs for MSCs
are not free of animal-derived components. They need
the flask surface to be coated with substrates isolated
from animal or human. These substrates are ill-defined
and vary significantly between different batches. When
compared with animal-derived materials, xeno-free coating
substrates that contain components derived from human
might be contaminated by communicable pathogens and
thus might be more dangerous. While a previous study re-
ported that MSCs may proliferate in three-dimensional
cultures without serum and coating substance [39], the
three-dimensional system is expensive and not suitable
for large-scale expansion to clinical application. To im-
prove cell attachment, a plasma surface treatment is used
Figure 6 Validation of the mRNA chip by real-time PCR. Relative expression levels were calculated by log2(fold change): log2(fold change) > 1,
increasing at least twice; log2(fold change) < −1, decreasing at least twice. Among the 12 genes we validated, only PRKCA showed an inconsistent
expression profile. When analyzed by mRNA chip, the expression of PRKCA was downregulated more than twice. However, in the real-time PCR
(RT-PCR) analysis, the expression of PRKCA did not show a significant difference during the process of long-term culture in serum-free medium.
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commercial SFMs provided by different companies in this
study can hUC-MSCs attach and propagate well on the
plasma-treated surface. Being similar to the bone marrow-
derived MSCs cultured in autologous serum [40], hUC-
MSCs cultured in SFM require more prolonged exposure
to trypsin to dissociate from the plastic surface than hUC-
MSCs cultured in SCM. This could be explained, based
on the data of transcriptome analysis, by upregulation
of many molecules related to cell adhesion (GPNMB,CXCL12, COL21A1, ITGBL1). However, we found that
hUC-MSCs cultured in SFM could be detached much eas-
ier in collagenase compared with trypsin.
Here, we build a system with a xeno-free, serum-free,
chemically defined medium and a chemically treated cul-
ture surface to expand hUC-MSCs. Neither animal-derived
or human-derived protein, nor ill-defined component is in-
cluded in our culture system. This is a stable, safe, control-
lable system and thus is suitable for preparing hUC-MSCs
for clinical application. The growth rate of hUC-MSCs in
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http://stemcellres.com/content/5/6/132this system was lower than in SCM, but all hUC-MSCs in
this study could propagate for at least seven passages,
which means the amount of hUC-MSCs could be amplified
more than 2,000 times (about 11 population doublings) be-
fore reaching the senescent stage. If the cell number of the
primary culture was 1 × 107 [22], we could obtain more
than 2 × 1010 hUC-MSCs at the seventh passage in SFM,
which met the quantity requirement of MSCs for clinical
applications.
hUC-MSCs derived from different donors showed a dif-
ferent lifespan in in vitro culture. Sometimes, the differ-
ence of lifespan between samples was very striking. In the
present study, sample 2 maintained proliferative capacities
even after 20 passages in SFM. However, sample 4 reached
senescence at the 10th passage in SFM. So, we cannot
analyze or evaluate SFM for MSCs only in one sample.
For fair reproducibility, SFM should be evaluated in MSCs
derived from different donors and different tissues.
Considering the close link between genome instability
and tumor genesis, whether SFM-expanded MSCs main-
tain genome stability is also an important safety issue for
clinical application. We utilized high-throughput aCGH
to evaluate the effect of long-term culture in SFM and
in SCM on genomic stability of hUC-MSCs in in vitro
culture. We found that hUC-MSCs gain copy number
changes in culture, no matter whether in SFM or in SCM.
This was consistent with the finding in adipose tissue-
derived MSCs [15], but differed from the data derived
from bone marrow-derived MSCs [33], which might be
caused by resolution of different methods. However, our
results did not support that hUC-MSCs possess better or
worse genome stability in SFM or in SCM.
Tumorigenicity is a most important safety issue when
cellular therapies are applied in clinical trials. Many
conventional and new technologies provide abundant
methods to analyze the genome stability and tumorigen-
icity. However, Prockop and Keating suggest that ‘the most
reliable and simplest test is: do the cells senesce in culture?
If they do, they are unlikely to produce tumors or malig-
nancies in patients’ [41]. Previous research has demon-
strated that MSCs are unlikely to undergo malignance
transformation after long-term culture in SCM [33]. Yet
this research did not answer well whether hUC-MSCs were
likely to transform or immortalize in SFM. In this study, all
hUC-MSC samples derived from five different donors
showed growth arrest and senescence in SFM. Thus, we
could conclude that hUC-MSCs derived from our culture
system, which consisted of SFM and a chemically treated
surface, did not undergo malignant transformation.
SFM-expanded hUC-MSCs showed a clear different
gene expression profile compared with hUC-MSCs cul-
tured in SCM based on our microarray data. Cell cycle,
mitosis and cell proliferation were downregulated in SFM-
expanded hUC-MSCs. We observed a low level of hTERTin SCM-expanded hUC-MSCs, which cannot be found in
SFM-expanded hUC-MSCs. Nevertheless, based on the
analysis of cell surface marker and multipotency, SFM-
expanded hUC-MSCs met the minimal criteria for human
MSCs [29]. The co-culture experiment also revealed that
SFM-expanded hUC-MSCs maintained their immunosup-
pressive ability, which is consistent with previous studies
[19,20]. The change of biological characteristics that was
found in SFM-expanded hUC-MSCs might not influence
their future clinical applications.
Conclusions
We studied biological characteristics and therapeutic po-
tential of hUC-MSCs that were expanded in a serum-free
and chemically defined culture. Our results indicated that
many growth rate-related biological characteristics of hUC-
MSCs were altered in SFM. However, SFM-expanded hUC-
MSCs met the basic criteria for human MSCs and also
maintained immunosuppressive ability. Besides, SFM ex-
pansion did not change the genetic stability of hUC-MSCs.
SFM-expanded hUC-MSCs are therefore suitable for clin-
ical application.
Additional file
Additional file 1: Figure S1. Showing quantification of hTERT and
RPLP0 mRNA in SFM-expanded hUC-MSCs and HeLa (positive control) by
TaqMan based real-time PCR. No expression of hTERT was detected in
SFM-expanded hUC-MSCs derived from five different donors. HeLa were
hTERT-positive.
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